ReviewPrzeglad menopauzalny = Menopause review2025
Does FIGO 2023 meet clinical needs? An analysis of challenges and limitations.
Review in Przeglad menopauzalny = Menopause review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Minimal Residual Disease Detection: Bridging Molecular and Clinical Strategies for Recurrence Prevention in Gynecologic Cancers.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The International Federation of Gynecology and Obstetrics (FIGO) 2023 classification for endometrial cancer (EC) introduces significant changes by integrating molecular subtypes (POLEmut, mismatch repair deficient, p53abn, no specific molecular profile) with traditional anatomical and pathological criteria. Key updates include an expanded number of substages, the incorporation of lymphovascular space invasion (LVSI) as a prognostic factor, and a novel division of tumors into aggressive and non-aggressive categories, reflecting advancements in oncology. These updates enhance prognostic precision and inform therapeutic strategies. Non-aggressive tumors, such as low-grade endometrioid carcinomas (G1 and G2), are associated with favorable outcomes and limited invasiveness. For these cases, factors like LVSI and depth of myometrial invasion support individualized approaches, including the potential for therapy de-escalation. Aggressive tumors, including high-grade endometrioid carcinomas (G3), serous and clear cell carcinomas, and p53abn subtypes, exhibit a higher risk of recurrence and metastasis, requiring intensified treatments. However, variability in molecular and histopathological assessments poses challenges to risk stratification within this group. Despite its potential to personalize treatment, the FIGO 2023 system presents implementation challenges. Variability in assessing LVSI, sentinel lymph node ultrastaging, and molecular markers highlights the need for standardized diagnostic criteria. Additionally, tumor heterogeneity complicates classification and therapeutic decisions, necessitating more advanced diagnostic approaches. The future success of the FIGO 2023 classification depends on harmonizing diagnostic standards, improving access to molecular technologies, and validating prognostic implications through prospective studies. While this update represents a significant step forward in tailoring EC management, further refinements are required to address diagnostic and implementation challenges and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.